Author:
Isenberg Jeff S.,Martin-Manso Gema,Maxhimer Justin B.,Roberts David D.
Publisher
Springer Science and Business Media LLC
Subject
General Earth and Planetary Sciences,General Environmental Science
Reference184 articles.
1. Pande, A., Lombardo, J., Spangenthal, E. & Javle, M. Hypertension secondary to anti-angiogenic therapy: experience with bevacizumab. Anticancer Res. 27, 3465–3470 (2007).
2. Wu, S., Chen, J. J., Kudelka, A., Lu, J. & Zhu, X. Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis. Lancet Oncol. 9, 117–123 (2008).
3. van Heeckeren, W. J. et al. Complications from vascular disrupting agents and angiogenesis inhibitors: aberrant control of hemostasis and thrombosis. Curr. Opin. Hematol. 14, 468–480 (2007).
4. Ku, D. D., Zaleski, J. K., Liu, S. & Brock, T. A. Vascular endothelial growth factor induces EDRF-dependent relaxation in coronary arteries. Am. J. Physiol. 265, H586–H592 (1993). The first report that VEGFA is an acute vasodilator.
5. Yang, R. et al. Effects of vascular endothelial growth factor on hemodynamics and cardiac performance. J. Cardiovasc. Pharmacol. 27, 838–844 (1996).
Cited by
248 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献